| Title |
|
Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up. |
|
|
| Publication Date |
|
| Author(s) |
|
| Subject |
|
autoimmune biliary disease |
|
|
cholestatic liver diseases |
|
|
| Type of document |
|
| OrcId |
|
| DOI |
|
10.1136/bmjgast-2020-000487 |
|
|
| Abstract |
|
Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long-term outcomes are particularly lacking. We present a biopsy-proven case of nivolumab-induced sclerosing cholangitis, which uniquely captures 18 months of follow-up post-treatment. Our case highlights key features of intrahepatic subtype sclerosing cholangitis and suggests durable response to corticosteroid therapy. |
|
|
| Link |
|
| Citation |
|
BMJ Open Gastroenterology 2020; 7(1): e000487 |
|
|
| Jornal Title |
|
BMJ Open Gastroenterology |
|
|
| ISSN |
|
